| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378538 | Bioorganic & Medicinal Chemistry Letters | 2005 | 4 Pages |
Abstract
A novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure–activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
Graphical abstractA novel class of 2,3-diaminopyridine bradykinin B1 receptor antagonists and related SAR studies are disclosed.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Dong-Mei Feng, Jenny M. Wai, Scott D. Kuduk, Christina Ng, Kathy L. Murphy, Richard W. Ransom, Duane Reiss, Raymond S.L. Chang, Charles M. Harrell, Tanya MacNeil, Cuyue Tang, Thomayant Prueksaritanont, Roger M. Freidinger, Douglas J. Pettibone,